Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.32 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.31 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.31 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.31 |
| ▸ | OXTR | P30559 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12886364 | 0.83 | GPR3 (0.40) | FFAR1FFAR4NOTUMSLC6A4HTR2A | |
| SCHEMBL18734030 | 0.83 | SLC6A4 (0.38) | KMT2ANOTUMSLC6A4HTR2AKCNH2 | |
| SCHEMBL13008512 | 0.81 | HSPB1 (0.42) | — | |
| SCHEMBL6764191 | 0.81 | CA3 (0.38) | SLC6A4HTR2AKCNH2 | |
| SCHEMBL13475540 | 0.78 | CYP2C9 (0.47) | KMT2AACHEHTTSMN1; SMN2 | |
| SCHEMBL18356035 | 0.78 | NFE2L2 (0.46) | ACHEHTTSMN1; SMN2 | |
| SCHEMBL21974055 | 0.78 | KCNH2 (0.30) | KCNH2 | |
| SCHEMBL20045039 | 0.78 | FFAR1 (0.38) | FFAR1FFAR4KCNH2 | |
| SCHEMBL15341306 | 0.77 | KIF11 (0.41) | NOTUMSLC6A4SLC6A2 | |
| SCHEMBL26019653 | 0.76 | DRD2 (0.41) | HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119400-A1 | QUINAZOLINE AND INDOLE COMPOUNDS TO TREAT MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2022-04-21 | — | — | US | disclosed |
| US-11248000-B2 | Quinazoline and indole compounds to treat medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-11072595-B2 | Benzothiophene-based selective estrogen receptor downregulator compounds | The Board of Trustees of lhe University of Illinois (US) | 2021-07-27 | — | — | US | disclosed |
| US-10981887-B2 | Benzothiophene estrogen receptor modulators | G1 THERAPEUTICS, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-10961252-B2 | Quinazoline and indole compounds to treat medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200216406-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS | G1 THERAPEUTICS, INC. (US) | 2020-07-09 | — | — | US | disclosed |
| US-20200165262-A1 | Quinazoline and Indole Compounds to Treat Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-05-28 | — | — | US | disclosed |
| US-10633362-B2 | Benzothiophene estrogen receptor modulators | G1 THERAPEUTICS, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190135825-A1 | Quinazoline and Indole Compounds to Treat Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-20190119243-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS | G1 THERAPEUTICS, INC. (US) | 2019-04-25 | — | — | US | disclosed |
| US-10208011-B2 | Benzothiophene estrogen receptor modulators | G1 THERAPEUTICS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170166551-A1 | BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR COMPOUNDS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170166551-A1 | BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR COMPOUNDS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-06-15 | — | — | US | disclosed |
| US-8304536-B2 | Phthalocyanine compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8183238-B2 | Bicyclic and tricyclic compounds as KAT II inhibitors | PFIZER INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | PFIZER INC | 2010-12-23 | — | — | US | disclosed |
| US-20100228021-A1 | PHTHALOCYANINE COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | KAT2A, KAT2B, KAT6B | FFAR1 3331/4885FFAR4 4389/4885KMT2A 48/4885 |
| US-10981887-B2 | Benzothiophene estrogen receptor modulators | ESR1, GPER1, ESR2 | FFAR1 403/4885FFAR4 390/4885KMT2A 777/4885 |
| US-20170166551-A1 | BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR COMPOUNDS | ESR1, ESR2, GPER1 | FFAR1 619/4885FFAR4 612/4885KMT2A 897/4885 |
| US-11248000-B2 | Quinazoline and indole compounds to treat medical disorders | CFB, TFPI, MAOB | FFAR1 4469/4885FFAR4 3809/4885KMT2A 4435/4885 |
| US-20220119400-A1 | QUINAZOLINE AND INDOLE COMPOUNDS TO TREAT MEDICAL DISORDERS | CFB, TFPI, MAOB | FFAR1 4469/4885FFAR4 3809/4885KMT2A 4435/4885 |
| US-10208011-B2 | Benzothiophene estrogen receptor modulators | ESR1, GPER1, ESR2 | FFAR1 403/4885FFAR4 390/4885KMT2A 777/4885 |
| US-10961252-B2 | Quinazoline and indole compounds to treat medical disorders | CFB, TFPI, MAOB | FFAR1 4469/4885FFAR4 3809/4885KMT2A 4435/4885 |
| US-20200165262-A1 | Quinazoline and Indole Compounds to Treat Medical Disorders | CFB, TFPI, MAOB | FFAR1 4469/4885FFAR4 3809/4885KMT2A 4435/4885 |
| US-20200216406-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS | ESR1, GPER1, ESR2 | FFAR1 403/4885FFAR4 390/4885KMT2A 777/4885 |
| US-11072595-B2 | Benzothiophene-based selective estrogen receptor downregulator compounds | ESR1, ESR2, GPER1 | FFAR1 619/4885FFAR4 612/4885KMT2A 897/4885 |
| US-20190135825-A1 | Quinazoline and Indole Compounds to Treat Medical Disorders | CFB, TFPI, MAOB | FFAR1 4469/4885FFAR4 3809/4885KMT2A 4435/4885 |
| US-10633362-B2 | Benzothiophene estrogen receptor modulators | ESR1, GPER1, ESR2 | FFAR1 403/4885FFAR4 390/4885KMT2A 777/4885 |
| US-20190119243-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS | ESR1, GPER1, ESR2 | FFAR1 403/4885FFAR4 390/4885KMT2A 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.